Regeneron (REGN) Reports Positive 84-Week OPTIMA Trial Results for Pasatru in FOP Patients

gurufocus.com · 2026-10-12

On October 12, 2026, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the 84-week findings from its Phase 3 OPTIMA trial evaluating Pasatru in adults with

TickrTrends take: Regeneron reported positive 84-week results from its OPTIMA trial for Pasatru in fibrodysplasia ossificans progressiva patients, representing progress in a rare disease indication where treatment options remain limited. Given that TickrTrends currently rates REGN as fairly valued, investors monitoring the stock should observe whether this clinical validation translates into revenue contributions and market share gains in the rare disease space, which could support or challenge the current valuation assessment. The timing and magnitude of any commercial uptake for Pasatru will be important data points for determining whether the stock's current valuation level remains appropriate.

Read the full story at gurufocus.com →